rc 3095 has been researched along with 9,10-dimethyl-1,2-benzanthracene in 2 studies
Studies (rc 3095) | Trials (rc 3095) | Recent Studies (post-2010) (rc 3095) | Studies (9,10-dimethyl-1,2-benzanthracene) | Trials (9,10-dimethyl-1,2-benzanthracene) | Recent Studies (post-2010) (9,10-dimethyl-1,2-benzanthracene) |
---|---|---|---|---|---|
108 | 2 | 26 | 6,010 | 10 | 772 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Crean, DH; Liebow, C; Mang, TS; Penetrante, RB | 1 |
Kozacko, MF; Liebow, C; Mang, TS; Priore, RL; Schally, AV | 1 |
2 other study(ies) available for rc 3095 and 9,10-dimethyl-1,2-benzanthracene
Article | Year |
---|---|
Evaluation of porfimer sodium fluorescence for measuring tissue transformation.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Bombesin; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cheek; Cricetinae; Dihematoporphyrin Ether; Disease Models, Animal; Fluorescence; Mesocricetus; Mouth Neoplasms; Peptide Fragments; Photometry; Protein-Tyrosine Kinases; Somatostatin | 1993 |
Bombesin antagonist prevents CO2 laser-induced promotion of oral cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Bombesin; Cricetinae; Dihematoporphyrin Ether; Lasers; Mouth Neoplasms; Neoplasms, Radiation-Induced; Peptide Fragments; Precancerous Conditions; Time Factors | 1996 |